axs-02
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02746068)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Farnesyl diphosphate synthaseINHIBITOR
FDPS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- axs-02
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02746068 | Phase 3 | Mar 1, 2016 | Axsome Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1